Harper was named UNLV’s 14th permanent Director of Athletics on Jan. 1, 2022, and is in his fifth year. He also served as the department’s interim athletics director from August 2021 through the end of that year.

High gas prices, fuel prices and news of budget airline Spirit shutting down operations is hitting people across the country and here in our valley.

UNLV has extended athletic director Erick Harper on a four-year contract, interim President Chris Heavey announced today. Harper has led the department since 2022.

UNLV sports have captured 15 conference championships in Harper’s first four seasons, with 11 league coach of the year awards and multiple NCAA Tournament appearances.

Nearly 200 students across 47 teams put their classroom knowledge to the test, presenting their technology advancement ideas to a panel of industry judges.

Dr Jeffrey Cummings, of the University of Nevada, Las Vegas, has published an annual review of clinical trials for Alzheimer’s drugs for the past decade. The latest review, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, reveals a shifting approach to the disease, with fewer drugs designed to remove amyloid and more targeting tau, inflammation and other immune system pathways.

A major donation drew attention after the Lombardo admin’s firing of the state water engineer, whom the industry had complained about.

Manoj Sharma, a tenured professor of social and behavioral health at the University of Nevada, Las Vegas, told The Epoch Times that a constantly busy schedule keeps the brain in a state of high alert, resulting in rapid beta waves visible on an electroencephalogram (EEG). This chronic overactivation depletes energy, leading to stress, burnout, mental fatigue, poor sleep, decreased work efficiency, and emotional neglect.

Every year, world‑leading dementia researcher Dr Jeffrey Cummings releases a global snapshot of Alzheimer’s trials – and the 2026 update has just been published. Right now, researchers are evaluating 158 medicines across 192 trials – marking an impressive 40% rise over the past decade. This year’s review also shows the most diverse Alzheimer’s drug pipeline to date.